Leash Bio is leveraging advanced machine learning techniques to revolutionize drug discovery by focusing on the creation of a comprehensive dataset derived from extensive screening of millions of compounds against thousands of proteins. This approach has generated billions of data points, which are essential for training sophisticated machine learning models. By addressing the existing data gap in drug discovery, Leash Bio aims to identify potential blockbuster drugs more efficiently. Their proprietary dataset of protein-molecule interactions is a cornerstone of their technology, enabling rapid searches across vast chemical spaces and facilitating the design of new molecules with a higher likelihood of desired biological activity.

The company employs a dynamic, cyclical engine that continuously integrates new data, iterates on machine learning models, and refines its methodologies, with each cycle completed in just a few months. This innovative software platform allows for the rapid design and testing of novel chemical entities, having already measured over 17.4 billion protein-molecule interactions and produced 6.7 million machine learning-designed molecules. Looking ahead, Leash Bio plans to expand its capabilities by measuring 500 protein targets against 20 million molecules within the next year, while also developing new medicines and collaborating with biopharma partners to explore new opportunities in drug development.

United States

Leash Bio is a biotechnology company that is transforming drug design with a rich dataset built by screening millions of compounds against thousands of proteins to generate billions of data. They are pioneering AI-driven medicinal chemistry and unleashing machine learning to solve medicinal chemistry.

Leash Bio

Company Details